AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
🇿🇼
HYDROCHLOROTHIAZIDE; IRBESARTAN in Zimbabwe
4 products registered with MCAZ — 4 active
| Brand / Product | Reg. No. | Holder | Status | Expires |
|---|---|---|---|---|
| IRBESARTAN/HYDROCHLOROTHIAZIDE IMPACT TABLET, COATED; ORAL | 2026/12.3.5/7447 | SANOFI AVENTIS SOUTH AFRICA (PTY) | active | 1 Jun 2031 |
| IRBESARTAN/HYDROCHLOROTHIAZIDE IMPACT TABLET, COATED; ORAL | 2026/12.3.5/7446 | SANOFI AVENTIS SOUTH AFRICA (PTY) | active | 1 Jun 2031 |
| IRBIS-HT TABLET, COATED; ORAL | 2018/12.3.5/5668 | HETERO LABS LTD | active | 20 Apr 2031 |
| IRBIS-HT TABLET, COATED; ORAL | 2018/12.3.5/5669 | HETERO LABS LTD | active | 20 Apr 2031 |
HYDROCHLOROTHIAZIDE; IRBESARTAN — MCAZ Registration Details
MCAZ (Zimbabwe) has 4 registered products containing HYDROCHLOROTHIAZIDE; IRBESARTAN, of which 4 are currently active. Data is sourced directly from the official MCAZ drug register and refreshed daily.
Track HYDROCHLOROTHIAZIDE; IRBESARTAN registration expiry dates, monitor competitor approvals, and receive alerts when registration status changes. Create a free account to set up portfolio monitoring.